Jaguar Health, Inc. - JAGX STOCK NEWS

Jaguar Health, Inc. (NASDAQ:JAGX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 3:00 PM ET. Founder and CEO Lisa Conte will lead the presentation, which focuses on the company's innovative, plant-based pharmaceuticals for gastrointestinal distress. Institutional investors can register for the conference here to arrange one-on-one meetings with Jaguar.

Jaguar's Mytesi (crofelemer) is FDA-approved for noninfectious diarrhea relief in adults with HIV/AIDS.

Jaguar Health, Inc. (JAGX) announced a third amendment to its accounts receivable purchase agreement with Oasis Capital, LLC, allowing Oasis to purchase an additional $2,329,662.72 in accounts receivable related to the sales of Mytesi drug product. This financing aims to enhance the company's cash flow without diluting shareholder equity.

The agreement entails a purchase price of $990,106.65 and a transaction fee of $5,000. This follows the success of previous tranches and indicates Jaguar's commitment to a stable cash flow positive business strategy.

Jaguar Health, Inc. (JAGX) announced on September 2, 2020, it has completed transactions boosting its stockholders' equity above $5 million, meeting the Nasdaq Capital Market's initial listing requirement. Previously, the company reported $1,544,000 in equity at the end of June 2020. The transactions involved exchanging shares of preferred stock and issuing common stock, completed on September 1, 2020. These efforts aim to address a prior notification from Nasdaq regarding a breach of listing rules due to insufficient equity.

Jaguar Health, Inc. (NASDAQ:JAGX) provided updates on its investigator-initiated trials of crofelemer (Mytesi), a plant-based FDA-approved medication. Trials include: 1) Chronic Idiopathic Diarrhea, with full enrollment expected by 2020 year-end and results by mid-2021; 2) Functional Diarrhea, starting enrollment in Q4 2020 with results also anticipated in Q4 2021; and 3) Diarrhea in HER2-positive breast cancer patients, nearing enrollment completion with results due mid-2021. Mytesi uniquely treats noninfectious diarrhea in HIV/AIDS patients and aims to address significant healthcare costs associated with chronic diarrhea.

Jaguar Health, Inc. (NASDAQ:JAGX) has submitted the final technical section required by the FDA to seek approval for its oral plant-based drug, Canalevia, aimed at treating chemotherapy-induced diarrhea in dogs. With over 50,000 dogs affected annually, Canalevia would be the first FDA-approved medicine for this condition. The company anticipates conditional approval for both chemotherapy-induced and exercise-induced diarrhea by mid-2021. Jaguar’s subsidiary, Napo Pharmaceuticals, markets Mytesi, another crofelemer-based product for humans.

Jaguar Health (NASDAQ:JAGX) has submitted the final technical section to the FDA for approval of Canalevia, a plant-based drug to treat chemotherapy-induced diarrhea (CID) in dogs. This submission marks a significant step towards potentially becoming the first FDA-approved treatment for over 50,000 affected dogs annually. The filing supports conditional approval under the Minor Use/Minor Species Act. Jaguar also plans to seek approval for treating exercise-induced diarrhea. Canalevia aims to improve comfort and chemotherapy tolerance in dogs.

Jaguar Health (NASDAQ:JAGX) announced an amendment to its accounts receivable purchase agreement with Oasis Capital, LLC. This agreement involves the purchase of additional accounts receivable worth $3,152,545 related to Mytesi drug sales. Oasis will pay $1,339,831.83, with a fee of 5.45% on the total amount. The company aims to secure non-dilutive capital to enhance its cash flow. Mytesi is approved for treating noninfectious diarrhea in HIV/AIDS patients.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a second amendment to its accounts receivable purchase agreement with Oasis Capital for the purchase of additional accounts receivable valued at $3,152,545 related to the sales of Mytesi drug product. Following this amendment, the Company will receive $1,339,831.83 after Oasis charges a 5.45% fee. The financing aims to support Jaguar's strategy to secure non-dilutive capital and work towards becoming a cash flow positive business.

Jaguar Health reported significant growth in Mytesi sales for Q2 2020, with net sales reaching approximately $3.2 million, a 186% increase from $1.7 million in Q2 2019. Gross sales also saw a substantial rise, hitting about $6.3 million, reflecting 268% growth year-over-year. Loss from operations decreased to $8.45 million, improved by lower operating expenses and increased product pricing. Meanwhile, net loss significantly reduced by 45% to $9.24 million. A virtual disease education event is scheduled for October 20, 2020, to discuss cancer therapy-related diarrhea.